Clinical Trial

Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A phase II, open-label, multicenter study to evaluate the efficacy and safety of oral TT-00420 (Tinengotinib) tablets in subjects with cholangiocarcinoma who failed or relapsed to prior treatment of chemotherapy and FGFR Inhibitor.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-26; most recent amendment 2025-08-15.
Status change: Recruiting → Active, Not Recruiting 2025-08-15
Status change: Not Yet Recruiting → Recruiting 2023-12-27
Trial Details
NCT Number NCT06057571
Lead Sponsor TransThera Sciences (Nanjing), Inc.
Conditions Cholangiocarcinoma Metastatic
Enrollment 50 participants
Start Date 2023-11-17
Primary Completion 2025-07-27 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-21